SCHEMBL4904652

SCHEMBL4904652

CC[C@@H](C)Nc1ccc(C#N)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
TP53 P04637 1/20 0.52
HSP90AA1 P07900 1/20 0.52
CYP3A4 P08684 1/20 0.52
THRB P10828 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
CASP1 P29466 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
IDO1 P14902 1/20 0.46
RORC P51449 6/20 0.43
SLC22A12 Q96S37 4/20 0.43
TRPV4 Q9HBA0 1/20 0.42
AR P10275 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904656 1.00 ALDH1A1 (0.52) ALDH1A1TP53HSP90AA1CYP3A4THRB
SCHEMBL5174565 0.89 ALDH1A1 (0.41) ALDH1A1TP53HSP90AA1CYP3A4THRB
SCHEMBL23172500 0.86 IDO1 (0.48) ALDH1A1IDO1RORCSLC22A12TRPV4
SCHEMBL23134576 0.86 IDO1 (0.48) ALDH1A1IDO1RORCSLC22A12TRPV4
SCHEMBL4904892 0.85 ALDH1A1 (0.57) ALDH1A1TP53HSP90AA1CYP3A4THRB
SCHEMBL4904887 0.85 ALDH1A1 (0.57) ALDH1A1TP53HSP90AA1CYP3A4THRB
SCHEMBL12744490 0.80 ALDH1A1 (0.63) ALDH1A1TP53HSP90AA1CYP3A4THRB
SCHEMBL4905335 0.79 RORC (0.44) ALDH1A1IDO1RORCSLC22A12TRPV4
SCHEMBL4894261 0.79 RORC (0.44) ALDH1A1IDO1RORCSLC22A12TRPV4
SCHEMBL3031576 0.78 RORC (0.43) ALDH1A1IDO1RORCARLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045504-A1 Benzonitrile Derivatives to Treat Musculoskeletal Frailty PFIZER PRODUCTS INC. (US) 2008-02-21 US disclosed
EP-1747193-A1 BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY Pfizer Products Incorporated (US) 2007-01-31 EP disclosed
WO-2006024931-A2 THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR PFIZER PRODUCTS INC. (US) 2006-03-09 WO disclosed
WO-2005108351-A1 BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY PFIZER PRODUCTS INC. (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045504-A1 Benzonitrile Derivatives to Treat Musculoskeletal Frailty TNNC1, TNNI3, TNNT2 ALDH1A1 1931/4885TP53 706/4885HSP90AA1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.